Peng Liu

180 Fenglin Road
Xuhui, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 279 publications

Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis.

Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis.

Journal: Hematological oncology

Published: May 21, 2026

Electrochemical Modulation of Precatalysts Tailors the Cu Coordination Environment to Shift CO2RR Products from C1 to C2.

Electrochemical Modulation of Precatalysts Tailors the Cu Coordination Environment to Shift CO2RR Products from C1 to C2.

Journal: ACS nano

Published: May 12, 2026

Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.

Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.

Journal: JAMA

Published: April 22, 2026

Toxic effects of combined exposure to tebuconazole and perfluorooctanoic acid on Eisenia fetida: an assessment based on behavioral, biochemical, and molecular levels.

Toxic effects of combined exposure to tebuconazole and perfluorooctanoic acid on Eisenia fetida: an assessment based on behavioral, biochemical, and molecular levels.

Journal: Environmental pollution (Barking, Essex : 1987)

Published: March 24, 2026

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.

Journal: American journal of hematology

Published: March 23, 2026

The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma.

The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma.

Journal: Blood cancer journal

Published: March 22, 2026

Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study.

Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study.

Journal: PloS one

Published: March 14, 2026

Long-term outcomes of autologous cell transplantation for patients with non-TAO autoimmune disease-related critical limb ischemia.

Long-term outcomes of autologous cell transplantation for patients with non-TAO autoimmune disease-related critical limb ischemia.

Journal: Cell transplantation

Published: March 03, 2026

Integrative transcriptomics elucidates core regulatory network governing human megakaryopoiesis: Insights from CD34+-derived megakaryocyte maturation.

Integrative transcriptomics elucidates core regulatory network governing human megakaryopoiesis: Insights from CD34+-derived megakaryocyte maturation.

Journal: Thrombosis research

Published: January 25, 2026

First-line Polatuzumab vedotin plus R-CHP in primary mediastinal B-cell lymphoma: A real-world study bridging the gap of the POLARIX trial.

First-line Polatuzumab vedotin plus R-CHP in primary mediastinal B-cell lymphoma: A real-world study bridging the gap of the POLARIX trial.

Journal: Annals of hematology

Published: January 23, 2026

Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia.

Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia.

Journal: Immunotherapy

Published: January 23, 2026

Neurotoxic effects of spirotetramat in zebrafish (Danio rerio): Brain injury, locomotor abnormalities, and altered visual-related pathways.

Neurotoxic effects of spirotetramat in zebrafish (Danio rerio): Brain injury, locomotor abnormalities, and altered visual-related pathways.

Journal: Journal of hazardous materials

Published: January 12, 2026

Showing 1-12 of 279

Last Updated: 09/26/2026